Evaluation of Ciprofloxacin for Inhalation to Cystic Fibrosis Patients With P. Aeruginosa
Status:
Withdrawn
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2a, multicenter study, designed to evaluate the pharmacokinetics, safety,
and tolerability of once daily administration of 150 mg of Ciprofloxacin for Inhalation (CFI)
in patients with Cystic Fibrosis who have a history of chronic P. aeruginosa lung infection.